Proinflammatory factors in children with juvenile idiopathic arthritis
More details
Hide details
Online publication date: 2010-04-09
Reumatologia 2010;48(1):62-65
Juvenile idiopathic arthritis is the most common chronic arthropathy in childhood. According to ILAR criteria JIA is defined as persistent arthritis for more than 6 weeks with an onset at less than 16 years of age. JIA consists of six subtypes. Macrophages, dendritic cells and lymphocytes T are of great importance in pathogenesis of the disease. Prolonged activation of these cells leads to imbalance between concentrations of pro- and anti-inflammatory factors, which sustain inflammatory process. Many researches confirm elevated levels of interleukin 1b, interleukin 6 and tumor necrosis factor in serum and synovial fluid of JIA patients (depending on disease subtype). Evaluation of serum and synovial concentrations of IL-1b, IL-6, TNF-α can make earlier diagnosis of active inflammatory process possible, in case of normal results of other laboratory tests. It will allow to establish earlier diagnosis of JIA and prognosis for future. In addition in some cases it will let to decide on earlier onset of biological treatment.
Rostropowicz-Denisiewicz K. Młodzieńcze idiopatyczne zapalenie stawów. W: Zapalne choroby reumatyczne w wieku rozwojowym. Romicka AM, Rostropowicz-Denisiewicz K (red.). Wy-dawnictwo Lekarskie PZWL, Warszawa 2005; 71-87.  .
Choy EHS, Panai GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. NEJM 2003; 344: 907-916.  .
Górska A, Urban M, Pietrewicz E. Stężenie cytokin w surowicy u pacjentów z młodzieńczym idiopatycznym zapaleniem stawów. Reumatologia 2004; 42: 174-175.  .
Górska A, Urban M, Pietrewicz E. Zawartość kwasu linolowego i arachidonowego w fosfatydylocholinie błon erytrocytarnych oraz IL-6 i TNF-α w surowicy a stężenie białka C-reaktywnego u dzieci chorych na młodzieńcze idiopatyczne zapalenie stawów. Pol Merk Lek 2006; 21: 551-553.  .
Pietrewicz E, Urban M, Górska A. Stężenie cytokin w surowicy u pacjentów z młodzieńczym idiopatycznym zapaleniem stawów w zależności od postaci choroby i stopnia jej aktywności. Nowa Pediatria 2003; 1: 36-37.  .
Quarta L, Corrado A, Melillo N, et al. Juvenile idiopathic arthritis: an update on clinical and therapeutic approach. Ann Ital Med Int 2005; 20: 211-217.  .
Wilkinson N, Jackson G, Gardner-Medwin J. Biologic therapies for juvenile arthritis. Arch Dis Child 2003; 8: 186-191.  .
Moeller B, Villiger PM. Inhibition of IL-1, IL-6, and TNF-α in immune-mediated inflammatory diseases. Springer Semin Immunol 2006; 27: 391-408.  .
de Jager W, Hoppenrereijs EP, Wulffraat NM, et al. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis; cross-sectional study. Ann Rheum Dis 2007; 66: 589-598. .
Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Ann Rev Immunol 2001; 19: 163-196. .
Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008; 118: 3537-3545. .
Kim EY, Moudgil KD. Regulation of autoimmune inflammation by pro-inflammatory cytokines. Immunology Letters 2000; 120: 1-5. .
Jelusic M, Lukic IK, Tambic-Bukovac L, et al. Interleukin 18 as mediator of systemie juvenile idiopathic arthritis. Clin Rheumatol 2007; 26: 1332-1334. .
Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117: 244-279. .
Gołąb J, Jakóbisiak M, Zagożdżon R i wsp. Cytokiny. W: Immunologia. Gołąb J, Jakóbisiak M, Lasek W (red.). Wydawnictwo Naukowe PWN, Warszawa 2002; 204-245. .
Yokota S, Miyamae T, Imagawa T, et al. Inflammatory cytokines and systemic–onset juvenile idiopathic arthritis. Mod Rheumatol 2004; 14: 12-17. .
Łukaszewicz M, Mroczko B, Szmitkowski M. Znaczenie klini-czne interleukiny 6 jako czynnika rokowniczego w chorobie nowotworowej. Pol Arch Med Wewn 2007; 117: 5-6. .
Pascual V, Allantaz F, Arce E, et al. Role of interleukin in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. JEM 2005; 201: 1479-1486. .
Prahalad S, Martins T, Tebo AE, et al. Elevated serum levels of soluble CD154 in children with juvenile idiopathic arthritis. Ped Rheumatol 2008; 6: 8. .
Romicka AM. Młodzieńcze idiopatyczne zapalenie stawów. Przewodnik Lekarza 2001; 12: 35-38. .
Yokota S, Miyamae T, Imagawa T, et al. Therapeutic Efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic onset juvenile idiopathic arthritis. Arthritis Rheum 2005; 52: 818-825. .
Luqmani R, Sheeran T, Robinson M, et al. Systemic cytokine measurements: their role in monitoring the response therapy in patients with rheumatoid arthritis. Clin Exp Rheumatol 1994; 12: 503-508. .
Levaelampi T, Honkanen V, Lahdenne P, et al. Effects of infliximab on cytokines, myeloperoxidase and soluble adhesion molecules In patients with juvenile idiopathic arthritis. Scand J Rheumatol 2007; 36: 189-193. .
Fabre S, Dupuy AM, Dossat N, et al. Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis. Clin Exp Immunol 2008; 153: 188-195. .
Song IH, Appel H, Haibel H, et al. New onset of Crohn’s disease during treatment of active ankylosing spondylitis with etanercept. J Hematol 2008; 35: 532-536. .
Bhatia A, Kast RE. Tumor necrosis factor can paradoxically increase on etanercept treatment, occasionally contributing to TNF-mediated disease. J Rheumatol 2007; 34: 447-449.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Journals System - logo
Scroll to top